CHEK1 and cancer: Our work in unraveling the mechanism that drives p53-deficient cells to activate NF-кB in response to doxorubicin provides evidence that inhibiting CHK1 in these cancers maybe a better alternative, as targeting transcription factors has proven challenging [29].